文献速递MDS 与骨髓增殖性肿瘤血栓与止血

罗米司亭单药治疗伴血小板减少的骨髓增生异常综合征患者:长期安全性与疗效

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
PubMed 文献 · Br J Haematol · 2017-06-14

这项开放标签扩展研究评估罗米司亭单药治疗60例低危或中危1型骨髓增生异常综合征(MDS)且血小板计数≤50×10^9/L患者的长期安全性与疗效。治疗相关不良事件发生率为14/60(23%),严重不良事件为4/60(7%),2例进展为急性髓系白血病;34例(57%)有血小板反应,中位反应持续时间33周,28/34(82%)为持续反应。

要点

  • 治疗相关不良事件14/60(23%),严重不良事件4/60(7%),无新的安全性问题。
  • 2例患者分别在第44周和第46周进展为急性髓系白血病。
  • 34例(57%)有血小板反应,中位反应持续时间33周,28/34(82%)为持续反应。

核心结论

  • 罗米司亭单药治疗低危或中危1型MDS伴血小板减少患者无新的安全性问题,进展为急性髓系白血病的发生率低,多数患者的血小板反应得以维持。

研究设计与样本

  • 开放标签扩展研究,纳入60例低危或中危1型MDS且血小板计数≤50×10^9/L的患者,评估罗米司亭单药治疗的长期安全性与疗效。
  • 主要终点为不良事件发生率,次要终点包括出血事件和血小板反应等疗效参数。

主要发现

  • 扩展研究中的中位(范围)治疗时间为25(2-181)周,此后中位观察时间为57(11-209)周。
  • 治疗相关不良事件发生于14/60(23%)患者,严重不良事件发生于4/60(7%)患者。
  • 2例患者分别在第44周和第46周进展为急性髓系白血病。
  • 34例(57%)患者有血小板反应,中位(范围)反应持续时间为33(7-174)周;28/34(82%)患者为持续反应。
  • 34例中有5例(15%)发生≥3级出血事件,其中3例发生在血小板计数>50×10^9/L时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Romiplostim can improve platelet counts in about 50% of patients with low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long-term toxicity and efficacy are not known. This open-label extension study evaluated the long-term safety and efficacy of romiplostim in 60 patients with lower risk MDS and platelet counts ≤50 × 109 /l. The primary endpoint was adverse event (AE) incidence. Secondary endpoints were efficacy parameters, including bleeding events and platelet response. Median (range) treatment time in the extension study and the median observation times thereafter were 25 (2-181) and 57 (11-209) weeks, respectively. Treatment-related AEs and serious AEs were reported in 14/60 (23%) and 4/60 (7%) patients, respectively. Progression to acute myeloid leukaemia (AML) occurred in two patients after 44 and 46 weeks. Patients (n = 34, 57%) with a platelet response were further evaluated for length of response. Median (range) response duration was 33 (7-174) weeks; 28/34 (82%) patients had a continuous response. Five of 34 patients (15%) had grade ≥3 bleeding events; three when the platelet count was >50 × 109 /l. There were no new safety concerns and the rate of progression to AML was low; response to romiplostim was maintained for most patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017. PMID: 28616874. doi:10.1111/bjh.14792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。